AU2015340308B2 - Dopamine D3 receptor antagonists compounds - Google Patents
Dopamine D3 receptor antagonists compounds Download PDFInfo
- Publication number
- AU2015340308B2 AU2015340308B2 AU2015340308A AU2015340308A AU2015340308B2 AU 2015340308 B2 AU2015340308 B2 AU 2015340308B2 AU 2015340308 A AU2015340308 A AU 2015340308A AU 2015340308 A AU2015340308 A AU 2015340308A AU 2015340308 B2 AU2015340308 B2 AU 2015340308B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- phenyl
- azaspiro
- sulfanyl
- triazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*(C1)CC11CC*(C)CC1 Chemical compound C*(C1)CC11CC*(C)CC1 0.000 description 13
- OSEWZWOZEALWNZ-UHFFFAOYSA-N ClC1(C2(CCNCC2)C1c1ccccc1)Cl Chemical compound ClC1(C2(CCNCC2)C1c1ccccc1)Cl OSEWZWOZEALWNZ-UHFFFAOYSA-N 0.000 description 2
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1=O)=O ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- BTJDOXOFWZECOT-UHFFFAOYSA-N CC(CSc1nnc(-c2c(C)nc[o]2)[n]1C)CCl Chemical compound CC(CSc1nnc(-c2c(C)nc[o]2)[n]1C)CCl BTJDOXOFWZECOT-UHFFFAOYSA-N 0.000 description 1
- WBCYLBFMJMZEEQ-UHFFFAOYSA-N CC(c(nc1)cnc1-c1nnc(C)[n]1C)=C Chemical compound CC(c(nc1)cnc1-c1nnc(C)[n]1C)=C WBCYLBFMJMZEEQ-UHFFFAOYSA-N 0.000 description 1
- JMRWWKHCEVUJJU-KCWPFWIISA-N CCCC(N(CC1)CCC1c([n]1C)nnc1SCCCN(CC1)C[C@]1(C1)[C@H]1c1ccc(C(F)(F)F)cc1)=O Chemical compound CCCC(N(CC1)CCC1c([n]1C)nnc1SCCCN(CC1)C[C@]1(C1)[C@H]1c1ccc(C(F)(F)F)cc1)=O JMRWWKHCEVUJJU-KCWPFWIISA-N 0.000 description 1
- NIXXXNOOBQYVOB-UHFFFAOYSA-N C[n]1c(S)nnc1-c(cc1)nc2c1[nH]cn2 Chemical compound C[n]1c(S)nnc1-c(cc1)nc2c1[nH]cn2 NIXXXNOOBQYVOB-UHFFFAOYSA-N 0.000 description 1
- IDPMMNTWQRVEML-UHFFFAOYSA-N C[n]1c(SCCCCl)nnc1-c1cccc(-c2ncc[o]2)c1 Chemical compound C[n]1c(SCCCCl)nnc1-c1cccc(-c2ncc[o]2)c1 IDPMMNTWQRVEML-UHFFFAOYSA-N 0.000 description 1
- PQHIRTDXFUZNBI-XGLRFROISA-N C[n]1c(SCCCN(CC2)CC2(C2)[C@@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1ccc(C(N)=O)nc1 Chemical compound C[n]1c(SCCCN(CC2)CC2(C2)[C@@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1ccc(C(N)=O)nc1 PQHIRTDXFUZNBI-XGLRFROISA-N 0.000 description 1
- BVHNUWLFNKKLML-COFLGROHSA-N C[n]1c(SCCCN(CC2)CC2(C2)[C@H]2C2C=CC(C(F)(F)F)=CC2)nnc1-c1ccnnc1 Chemical compound C[n]1c(SCCCN(CC2)CC2(C2)[C@H]2C2C=CC(C(F)(F)F)=CC2)nnc1-c1ccnnc1 BVHNUWLFNKKLML-COFLGROHSA-N 0.000 description 1
- DOTLHOVQYVFUDB-CGHJUBPDSA-N C[n]1c(SCCCN(CC2)CC2(C2)[C@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1cccnc1OC Chemical compound C[n]1c(SCCCN(CC2)CC2(C2)[C@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1cccnc1OC DOTLHOVQYVFUDB-CGHJUBPDSA-N 0.000 description 1
- ACKJXZGTUCARLB-SIKLNZKXSA-N C[n]1c(SCCCN(CC2)C[C@@]2(C2)[C@@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1ccnnc1 Chemical compound C[n]1c(SCCCN(CC2)C[C@@]2(C2)[C@@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1ccnnc1 ACKJXZGTUCARLB-SIKLNZKXSA-N 0.000 description 1
- IQKUCRAAVAKXAF-SNJVWJBVSA-N C[n]1c(SCCCN(CC2)C[C@@]2(C2)[C@@H]2c2ccc(C(F)(F)F)cc2)nnc1C1CC(CC2)OC2C1 Chemical compound C[n]1c(SCCCN(CC2)C[C@@]2(C2)[C@@H]2c2ccc(C(F)(F)F)cc2)nnc1C1CC(CC2)OC2C1 IQKUCRAAVAKXAF-SNJVWJBVSA-N 0.000 description 1
- PQHIRTDXFUZNBI-CYFREDJKSA-N C[n]1c(SCCCN(CC2)C[C@]2(C2)[C@@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1ccc(C(N)=O)nc1 Chemical compound C[n]1c(SCCCN(CC2)C[C@]2(C2)[C@@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1ccc(C(N)=O)nc1 PQHIRTDXFUZNBI-CYFREDJKSA-N 0.000 description 1
- PQHIRTDXFUZNBI-DVECYGJZSA-N C[n]1c(SCCCN(CC2)C[C@]2(C2)[C@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1ccc(C(N)=O)nc1 Chemical compound C[n]1c(SCCCN(CC2)C[C@]2(C2)[C@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1ccc(C(N)=O)nc1 PQHIRTDXFUZNBI-DVECYGJZSA-N 0.000 description 1
- LKIZJVWLCHAZTJ-GCJKJVERSA-N C[n]1c(SCCCN(CC2)C[C@]2(C2)[C@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1ncncc1 Chemical compound C[n]1c(SCCCN(CC2)C[C@]2(C2)[C@H]2c2ccc(C(F)(F)F)cc2)nnc1-c1ncncc1 LKIZJVWLCHAZTJ-GCJKJVERSA-N 0.000 description 1
- IQKUCRAAVAKXAF-CEJRHITASA-N C[n]1c(SCCCN(CC2)C[C@]2(C2)[C@H]2c2ccc(C(F)(F)F)cc2)nnc1C1CC(CC2)OC2C1 Chemical compound C[n]1c(SCCCN(CC2)C[C@]2(C2)[C@H]2c2ccc(C(F)(F)F)cc2)nnc1C1CC(CC2)OC2C1 IQKUCRAAVAKXAF-CEJRHITASA-N 0.000 description 1
- FFCDNTCSZVWUHJ-OFNKIYASSA-N C[n]1c(SCCCN(CC2)C[C@]2(C2)[C@H]2c2ccccc2)nnc1C1CCOCC1 Chemical compound C[n]1c(SCCCN(CC2)C[C@]2(C2)[C@H]2c2ccccc2)nnc1C1CCOCC1 FFCDNTCSZVWUHJ-OFNKIYASSA-N 0.000 description 1
- RDKWVMMTTBBPQR-BDPMCISCSA-N C[n]1c(SCCCN(CCC(C2)[C@H]2c2ccc(C(F)(F)F)cc2)C#C)nnc1-c1ccc(C(N)=O)nc1 Chemical compound C[n]1c(SCCCN(CCC(C2)[C@H]2c2ccc(C(F)(F)F)cc2)C#C)nnc1-c1ccc(C(N)=O)nc1 RDKWVMMTTBBPQR-BDPMCISCSA-N 0.000 description 1
- YVHBUKOYKBLJPV-UHFFFAOYSA-N Cc1c(-c([n]2C)nnc2SCCCN(CC2)CC2(C2)C2c2ccc(C)cc2)[o]cn1 Chemical compound Cc1c(-c([n]2C)nnc2SCCCN(CC2)CC2(C2)C2c2ccc(C)cc2)[o]cn1 YVHBUKOYKBLJPV-UHFFFAOYSA-N 0.000 description 1
- WASVVAOFJXFXJW-HSTJUUNISA-N Cc1c(-c([n]2C)nnc2SCCCN(CC2)CC2(C2)[C@@H]2c2ccc(C)cc2C(F)(F)F)[o]cn1 Chemical compound Cc1c(-c([n]2C)nnc2SCCCN(CC2)CC2(C2)[C@@H]2c2ccc(C)cc2C(F)(F)F)[o]cn1 WASVVAOFJXFXJW-HSTJUUNISA-N 0.000 description 1
- JEBMPQYTJSNCNB-IBGZPJMESA-N Cc1c(-c([n]2C)nnc2SCCCN(CC2)CCC2(C2)[C@@H]2c2ccccc2)[o]cn1 Chemical compound Cc1c(-c([n]2C)nnc2SCCCN(CC2)CCC2(C2)[C@@H]2c2ccccc2)[o]cn1 JEBMPQYTJSNCNB-IBGZPJMESA-N 0.000 description 1
- JEBMPQYTJSNCNB-LJQANCHMSA-N Cc1c(-c([n]2C)nnc2SCCCN(CC2)CCC2(C2)[C@H]2c2ccccc2)[o]cn1 Chemical compound Cc1c(-c([n]2C)nnc2SCCCN(CC2)CCC2(C2)[C@H]2c2ccccc2)[o]cn1 JEBMPQYTJSNCNB-LJQANCHMSA-N 0.000 description 1
- RPKAUTYRVMDTGQ-JPYJTQIMSA-N Cc1c(-c([n]2C)nnc2SCCCN(CC2)C[C@]2(C2)[C@H]2c2ccc(C)cc2F)[o]cn1 Chemical compound Cc1c(-c([n]2C)nnc2SCCCN(CC2)C[C@]2(C2)[C@H]2c2ccc(C)cc2F)[o]cn1 RPKAUTYRVMDTGQ-JPYJTQIMSA-N 0.000 description 1
- LXCQXRDWKLZRPW-AUSIDOKSSA-N Cc1c(-c([n]2C)nnc2SCCCN(CC2)C[C@]2(CC2)[C@H]2c2ccccc2)[o]cn1 Chemical compound Cc1c(-c([n]2C)nnc2SCCCN(CC2)C[C@]2(CC2)[C@H]2c2ccccc2)[o]cn1 LXCQXRDWKLZRPW-AUSIDOKSSA-N 0.000 description 1
- QPSKWKOPXJGJKY-UHFFFAOYSA-N Cc1c(C(O)=C)[o]cn1 Chemical compound Cc1c(C(O)=C)[o]cn1 QPSKWKOPXJGJKY-UHFFFAOYSA-N 0.000 description 1
- LPZFPHRTKOOKLX-UHFFFAOYSA-N Cc1nnc(C)[n]1C Chemical compound Cc1nnc(C)[n]1C LPZFPHRTKOOKLX-UHFFFAOYSA-N 0.000 description 1
- JYDXPPMZWZFOID-UHFFFAOYSA-N FC(c1ccc(C(C2)C22CN(Cc3ccccc3)CCC2)cc1)(F)F Chemical compound FC(c1ccc(C(C2)C22CN(Cc3ccccc3)CCC2)cc1)(F)F JYDXPPMZWZFOID-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1419433.6A GB201419433D0 (en) | 2014-10-31 | 2014-10-31 | Dopamine D3 receptor antagonist compounds |
| GBGB1419430.2A GB201419430D0 (en) | 2014-10-31 | 2014-10-31 | Dopamine D3 receptor antagonist compounds |
| GB1419433.6 | 2014-10-31 | ||
| GB1419430.2 | 2014-10-31 | ||
| PCT/GB2015/053272 WO2016067043A1 (en) | 2014-10-31 | 2015-10-30 | Dopamine d3 receptor antagonists compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015340308A1 AU2015340308A1 (en) | 2017-05-11 |
| AU2015340308B2 true AU2015340308B2 (en) | 2019-09-19 |
Family
ID=54427799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015340308A Active AU2015340308B2 (en) | 2014-10-31 | 2015-10-30 | Dopamine D3 receptor antagonists compounds |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10000477B2 (enExample) |
| EP (1) | EP3212637B1 (enExample) |
| JP (1) | JP2017532364A (enExample) |
| KR (1) | KR20170090422A (enExample) |
| CN (1) | CN107108597B (enExample) |
| AU (1) | AU2015340308B2 (enExample) |
| CA (1) | CA2964103C (enExample) |
| DK (1) | DK3212637T3 (enExample) |
| ES (1) | ES2883831T3 (enExample) |
| IL (2) | IL251725B (enExample) |
| MA (1) | MA40858A (enExample) |
| MX (1) | MX2017005484A (enExample) |
| NZ (1) | NZ731118A (enExample) |
| RU (1) | RU2017118562A (enExample) |
| SG (1) | SG11201702982UA (enExample) |
| WO (1) | WO2016067043A1 (enExample) |
| ZA (1) | ZA201702765B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2964103C (en) * | 2014-10-31 | 2022-08-30 | Indivior Uk Limited | Dopamine d3 receptor antagonist compounds |
| CN106883192B (zh) * | 2017-03-30 | 2019-05-14 | 苏州汉德创宏生化科技有限公司 | 含氮类杂环抗肿瘤药物活性物恶唑基修饰的苯甲酸类化合物的合成方法 |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| TWI767148B (zh) * | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US12215105B2 (en) * | 2019-09-13 | 2025-02-04 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| PH12022550860A1 (en) | 2019-10-09 | 2023-06-14 | Novartis Ag | 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists |
| UY38906A (es) | 2019-10-09 | 2021-05-31 | Novartis Ag | Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos |
| CN110981795B (zh) * | 2019-12-18 | 2021-02-12 | 武汉世纪久海检测技术有限公司 | 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法 |
| US12698266B2 (en) | 2019-12-19 | 2026-08-04 | Casma Therapeutics, Inc. | TRPML modulators |
| TW202136253A (zh) * | 2019-12-19 | 2021-10-01 | 美商卡司馬療法公司 | Ｔｒｐｍｌ調節劑 |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| CN116120213B (zh) * | 2021-06-11 | 2024-09-13 | 重庆医药高等专科学校 | 反式4-(叔丁氧羰氨基)环己烷羧酸的合成方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013092893A1 (en) * | 2011-12-21 | 2013-06-27 | Rottapharm Spa | Chemical compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654305A (en) * | 1970-01-26 | 1972-04-04 | Robins Co Inc A H | 5-azaspiro(2.4)heptanes |
| CA2071897A1 (en) | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
| AU676993B2 (en) | 1991-06-27 | 1997-04-10 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| AU7314200A (en) | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| EP1248770A1 (en) | 1999-12-16 | 2002-10-16 | Biostream Therapeutics | 1,3,4-substituted piperidine analogs and uses thereof in treating addictions |
| MY145722A (en) | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
| DE60324544D1 (de) * | 2002-04-26 | 2008-12-18 | Schering Corp | Muskarin antagonisten |
| AU2005287037A1 (en) | 2004-09-20 | 2006-03-30 | Targacept, Inc. | Azaspiroalkene and azaspiroalkane compounds with nicotinic cholinergic receptor activity |
| GB0502509D0 (en) | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| US7977346B2 (en) | 2006-01-17 | 2011-07-12 | Guoqing Paul Chen | Spiro compounds and methods of use |
| WO2007098953A1 (en) | 2006-03-01 | 2007-09-07 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
| US20080247964A1 (en) | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| TW200813051A (en) * | 2006-05-08 | 2008-03-16 | Neurogen Corp | Substituted azaspiro derivatives |
| GB0700786D0 (en) | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
| GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| WO2012128582A2 (en) | 2011-03-23 | 2012-09-27 | Hyundai Pharm Co., Ltd. | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| US8809552B2 (en) | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| AR092289A1 (es) | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
| CA2964103C (en) * | 2014-10-31 | 2022-08-30 | Indivior Uk Limited | Dopamine d3 receptor antagonist compounds |
-
2015
- 2015-10-30 CA CA2964103A patent/CA2964103C/en active Active
- 2015-10-30 EP EP15790229.7A patent/EP3212637B1/en active Active
- 2015-10-30 KR KR1020177014318A patent/KR20170090422A/ko not_active Withdrawn
- 2015-10-30 CN CN201580071094.4A patent/CN107108597B/zh active Active
- 2015-10-30 ES ES15790229T patent/ES2883831T3/es active Active
- 2015-10-30 MA MA040858A patent/MA40858A/fr unknown
- 2015-10-30 RU RU2017118562A patent/RU2017118562A/ru not_active Application Discontinuation
- 2015-10-30 DK DK15790229.7T patent/DK3212637T3/da active
- 2015-10-30 WO PCT/GB2015/053272 patent/WO2016067043A1/en not_active Ceased
- 2015-10-30 SG SG11201702982UA patent/SG11201702982UA/en unknown
- 2015-10-30 JP JP2017523340A patent/JP2017532364A/ja active Pending
- 2015-10-30 US US15/522,863 patent/US10000477B2/en active Active
- 2015-10-30 AU AU2015340308A patent/AU2015340308B2/en active Active
- 2015-10-30 NZ NZ731118A patent/NZ731118A/en unknown
- 2015-10-30 MX MX2017005484A patent/MX2017005484A/es unknown
-
2017
- 2017-04-13 IL IL251725A patent/IL251725B/en active IP Right Grant
- 2017-04-19 ZA ZA2017/02765A patent/ZA201702765B/en unknown
-
2018
- 2018-05-09 US US15/975,466 patent/US10239870B2/en active Active
-
2019
- 2019-01-29 US US16/261,206 patent/US10654842B2/en active Active
-
2020
- 2020-07-30 IL IL276400A patent/IL276400A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013092893A1 (en) * | 2011-12-21 | 2013-06-27 | Rottapharm Spa | Chemical compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| DK3212637T3 (da) | 2021-07-12 |
| IL276400A (en) | 2020-09-30 |
| KR20170090422A (ko) | 2017-08-07 |
| US20180282318A1 (en) | 2018-10-04 |
| ZA201702765B (en) | 2019-05-29 |
| EP3212637B1 (en) | 2021-06-02 |
| IL251725A0 (en) | 2017-06-29 |
| ES2883831T3 (es) | 2021-12-09 |
| US10000477B2 (en) | 2018-06-19 |
| EP3212637A1 (en) | 2017-09-06 |
| RU2017118562A (ru) | 2018-11-30 |
| IL251725B (en) | 2020-08-31 |
| US20190300514A1 (en) | 2019-10-03 |
| MA40858A (fr) | 2021-03-31 |
| BR112017009042A2 (pt) | 2018-07-03 |
| AU2015340308A1 (en) | 2017-05-11 |
| CN107108597B (zh) | 2020-04-17 |
| US10239870B2 (en) | 2019-03-26 |
| MX2017005484A (es) | 2017-10-20 |
| NZ731118A (en) | 2023-05-26 |
| WO2016067043A1 (en) | 2016-05-06 |
| US20170334895A1 (en) | 2017-11-23 |
| CN107108597A (zh) | 2017-08-29 |
| CA2964103C (en) | 2022-08-30 |
| RU2017118562A3 (enExample) | 2019-05-28 |
| JP2017532364A (ja) | 2017-11-02 |
| US10654842B2 (en) | 2020-05-19 |
| CA2964103A1 (en) | 2016-05-06 |
| SG11201702982UA (en) | 2017-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10654842B2 (en) | Dopamine D3 receptor antagonist compounds | |
| AU2016303558B2 (en) | Dopamine D3 receptor antagonists having a bicyclo moiety | |
| KR100769030B1 (ko) | Ｃｇｒｐ 수용체 길항제 | |
| US8178549B2 (en) | Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors | |
| CA2648087A1 (en) | Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors | |
| EP1919908B1 (en) | Triazole derivatives as modulators of dopamine d3 receptors | |
| JP2011516398A (ja) | Ｎｐｙ−ｙ５アンタゴニストとしてのヘテロスピロ−デカン残基を有するベンズイミダゾール誘導体 | |
| WO2015161011A1 (en) | Benzamide cgrp receptor antagonists | |
| AU2016338992A1 (en) | Dopamine D3 receptor antagonists having a morpholine moiety | |
| HK1236519B (en) | Dopamine d3 receptor antagonists compounds | |
| HK1236519A1 (en) | Dopamine d3 receptor antagonists compounds | |
| US20100240661A1 (en) | Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors | |
| BR112017009042B1 (pt) | Composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
| WO2015161014A1 (en) | Heterocyclic cgrp receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |